shares
hit
ms
drug
suspension
shares
elan
biogen
idec
plunged
monday
firms
suspended
sales
new
multiple
sclerosis
drug
tysabri
patients
death
us
new
york
stock
exchange
shares
irelandbased
elan
lost
us
partner
biogen
idec
shed
firms
took
action
death
central
nervous
system
disease
suspected
case
condition
cases
cited
involved
use
tysabri
avonex
biogen
idecs
existing
multiple
sclerosis
drug
companies
said
reports
rare
condition
progressive
multifocal
leukoencephalopathy
pml
patients
taking
either
tysabri
avonex
alone
tysabri
approved
use
us
last
november
widely
tipped
become
worlds
leading
multiple
sclerosis
treatment
companies
work
clinical
investigators
evaluate
tysabritreated
patients
consult
leading
experts
better
understand
possible
risk
pml
two
firms
said
statement
outcome
evaluations
used
determine
possible
reinitiation
dosing
clinical
trials
future
commercial
availability
analysts
believed
product
would
provide
new
growth
opportunity
biogen
idec
faced
increased
competition
rivals
avonex
elan
biggest
firm
irish
stock
exchange
also
expected
receive
boost
new
product
inquiry
elans
accounts
brought
group
close
bankruptcy
firm
rebuilding
since
share
price
increasing
almost
fourfold
last
year
value
company
tysabri
said
ian
hunter
goodbody
stockbrokers
dublin
theres
question
mark
elan
finished
biogen
fell
shares
uk
pharmaceutical
firm
phytopharm
closed
pence
london
stock
exchange
monday
said
partner
set
pull
deal
experimental
alzheimers
disease
treatment
phytopharm
said
japans
yamanouchi
pharmaceutical
likely
end
licensing
agreement
prompting
analysts
raise
questions
level
future
cash
reserves
